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ABSTRACT
Objectives: To evaluate the clinical outcome of sequential therapy of gonadotropin-releasing hormone (GnRH) analog, followed by the levonorgestrel-
releasing intrauterine system in medically ill women with relatively large and symptomatic adenomyosis.
Methods: A prospective cohorts study conducted in the Obstetrics and Gynaecology Department, Al-Yarmouk teaching hospital in Baghdad/Iraq from 
June 2016 to January 2018. 32 women, 40 years and above who complete their family and had significant medical disease along with symptomatic 
and relatively large adenomyosis (≥150 cm3) were included in the study. The primary outcome measure was to evaluate the clinical outcome of this 
sequential therapy in the form of improving menstrual blood loss and pelvic pain and the secondary outcome was decreasing uterine volume.
Results: There were significant improvements in both menstrual blood loss volume and dysmenorrhea at the end of the 1st year with p˂0.001, mainly 
in the first 6 months. There were also significant reductions in the uterine volume (197.2±30.7–91.5±6.0 mm3). The expulsion rate was 15.6%.
Conclusion: Sequential treatment protocol of GnRH agonist - LNG-IUS in symptomatic and relatively large adenomyosis (˃150 cm3) is effective in 
relieving symptoms and decreasing uterine volume with less possible expulsion rate, making the protocol good substitutions to surgery, especially in 
medically ill women were surgery carry more risk.
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INTRODUCTION
Adenomyosis is a frequent cause of abnormal uterine bleeding (AUB), 
dysmenorrhea, and uterine enlargement in women in their reproductive 
years [1].
Histologically, it is defined as the benign invasion of the endometrium 
into the myometrium, producing a diffusely enlarged uterus which 
microscopically exhibits ectopic non-neoplastic, endometrial glands, 
and stroma surrounded by the hypertrophic and hyperplastic 
myometrium [2].
The average age of presentation is usually above 40 years, although it 
can be seen in young women [3] and its prevalence ranges from 5% to 
70%, and the rate of diagnosis during hysterectomy is approximately 
20–30% [4].
Gonadotropin-releasing hormone (GnRH) agonists were the first drugs 
used in the treatment of adenomyosis. They act by binding to GnRH 
receptors in the pituitary gland causing downregulation of GnRH 
activity and creating a reversible state of medically induced menopause. 
There is a reduction in uterine volume, amenorrhea, and relief of severe 
dysmenorrhea. However, discontinuation of treatments prompts 
regrowth of the uterus and results in recurrence of symptoms [5]. It is 
preferable to be used for limited periods of time (3–6 months) due to 
its side effects [6].
Levonorgestrel-releasing intrauterine system (LNG-IUS) is a 
highly effective treatment of heavy menstrual bleeding (HMB) in 
perimenopausal women. It is a safe, effective, and quality of life (QoL) 
after treatment makes it a good alternative to hysterectomy for HMB [7]. 
LNG-IUS is currently the best evaluated and the most efficacious 
treatment of adenomyosis-related symptoms with also a high rate of 
symptom improvement, few side-effects, and improvement of the QoL 
that is at least comparable to that of hysterectomy [8].
Multiple mechanisms may explain the role of the LNG-IUS in 
adenomyosis including decidualization of the endometrium followed 
by atrophic changes, through direct action on the adenomyotic foci; 
in addition downregulation of ER, in both glandular and stromal 
endometrial layers, occurs rapidly after placement of the device and 
persists for at least the 1st year of use. Treatment with the LNG-IUS 
also resulted in reduced lymphangiogenesis and lymphovascular 
density in the endometrial and myometrial tissues of patients with 
adenomyosis [9-12].
LNG-IU devices (LNG-IUDs) are spontaneously expulsed or removed 
from some women because of its failure to improve or worsening 
dysmenorrhea and/or menorrhagia. Heaver and larger uterine 
volume in women with adenomyosis could be a factor associated with 
discontinuation of the device [12,13].
The disadvantages of long-term administration of GnRHa in the form 
of cost, side effect, and possible rebound tendency of adenomyosis to 
recurs after discontinuation and using Mirena then after is suitable for 
long-term treatment for adenomyosis overcoming the possible cause 
of its initial expulsion, the combination of these two therapies could 
reduce the drawback-effect of GnRHa from one hand and reduce the 
expulsion rate of LNG-IUD from another hand.
In this study, we use GnRHa first to reduce uterine volume and blood 
loss and save time to correct anemia then followed by the placement 
of LNG-IUD. The primary outcome measure was to evaluate the clinical 
efficacy of this sequential therapy in medically ill women with relatively 
large and symptomatic adenomyosis.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i9.26847
Research Article
145
Asian J Pharm Clin Res, Vol 11, Issue 9, 2018, 144-148
 Alizzi 
METHODS
A prospective cohorts study conducted in the Obstetrics and Gynecology 
Department, Al-Yarmouk teaching hospital in Baghdad, Iraq, from 
June 2016 to January 2018 after approval of the ethical and scientific 
committee of the Obstetrics and Gynecology Department.
Women with adenomyosis diagnosed clinically and by ultrasound had 
been enrolled in the study after taking informed written consent from 
all participants; the inclusion criteria were age ≥40 years, who complete 
their family, with significant medical condition (hypertension, diabetes 
mellitus, heart, and renal disease), the participants’ have menorrhagia 
and pelvic pain with uterine volume ≥150 cm3. Patients were excluded 
from this study if they have leiomyomas and when the fertility is an 
issue.
Complete history and examination with baseline hemoglobin (Hb) were 
performed for all participant followed by a transvaginal ultrasound to 
confirm the diagnosis.
The ultrasound features used to diagnose adenomyosis was the presence 
of myometrial cysts, linear myometrial striations, and poor delineation 
of the endomyometrial junction, heterogeneous myometrium, and a 
globular and/or asymmetric uterus [14]. Uterine volume based on the 
sonographic parameters was calculated using the formula for a prolate 
ellipsoid; Volume = 0.5233 × D1 × D2 × D3 where D1 = maximum length 
(longitudinal dimension) D2 = maximum AP dimension D3 = maximum 
width (transverse dimension) [12].
Menstrual blood loss was estimated using a pictorial blood loss 
assessment chart and menorrhagia was defined when chart score = 100 
which was, in turn, equivalent to blood loss (80 mL) [15]. The presence 
and severity of dysmenorrhea were graded with a 10 cm visual analog 
pain scale (VAS), where mild pain 1–3, moderate 4–6, sever 7–9, and 
sever disabling pain=10 [16].
After the settlements of the diagnosis, all the participants are subjected 
to an outpatient endometrial biopsy to rule out other possible 
endometrial pathology [17].
Assessment of the risk of surgery (hysterectomy) with medical 
consultation had been done for all the participants, patient who was 
considered to have high risk for major surgery or low-to-intermediate 
risk, but refuses surgery as a first line were included in this study; all 
women showed no contraindications for the use of steroid hormones 
and intrauterine devices.
All the participants were asked to come in the first 2–3 days of the 
menstrual  cycle were a subcutaneous injection of Goserelin (Zoladex 3.6 
mg, AstraZeneca) were administered and repeated every 28 days until the 
uterine volume decreased to a volume <150 cm3. Total doses of goserelin 
used were 2–6 injection with no estrogen add-back therapy given.
When the uterine volume was determined to be <150 cm3 by 
transvaginal ultrasound, levonorgestrel-releasing intrauterine 
device - Mirena (Bayer, Germany) was implanted. Its position was 
confirmed to be in situ 10–14 days after insertion using transvaginal 
ultrasound and repeated 3 months later to exclude partial or complete 
dislodgment.
Medical management using non-steroidal anti-inflammatory drugs, 
antifibrinolytics-tranexamic acid if not contraindicated for the first 
2–3 months with cycle was given, and anemia was assessed and was 
corrected with folic acid supplements, iron sucrose [18].
The complete reassessment was done 6 months and 12 months after 
Mirena insertion by assessing menstrual blood loss and pain score with 
transvaginal ultrasound to assess uterine volume at each visit. Other 
outcome measures include encountered side effect of Mirena, failure 
and expulsion rate over 20-month follow-up period were recorded.
Statistical analysis
SPSS 20.0.0 (Chicago, IL), MedClac 14.8.1, and GraphPad Prism 
7.0 software package used to make the statistical analysis, p-value 
considered when appropriate to be significant if <0.05.
RESULTS
During the period of the study, 77 women had been diagnosed as 
adenomyosis, 32 of them met the inclusion criteria, the mean age of 
them was 46.6±2.69, and mean body mass index (BMI) 27.9±1.1. The 
mean menstrual blood loss using PMAC was 180±16.2 ml and mean pain 
4.75±0.8 using VAS. All of them had associated chronic medical diseases 
(hypertension, diabetes, heart disease, one case chronic renal disease, 
and one chronic obstructive airway disease) as shown in Table 1.
There was significant reduction in menstrual blood loss volume 
from pre-goserelin to end-of-using goserelin (180.0±16.2–57.8±3.8) 
p˂0.001, also there was significant change from after using goserelin 
to 6 months after using Marina (57.8±3.8–28.5±5.9) with p˂0.001, 
however, from 6 months post-Marina to 12 month post-Marina, there 
was no significant change (28.5±5.9–32.5±4.2), as illustrated in Fig. 1.
There was significant reduction in VAS score from pre-goserelin to end-
of-using goserelin (4.75±0.8–2.5±0.5), also there was significant change 
from after-using goserelin to 6 months after -using Marina (3.0±0.8); 
however, from 6-month post -Marina to 12-month post-Marina, there 
was no significant change (3.5±0.5), as illustrated in Fig. 2.
At baseline, uterine volume was 197.2±30.7 mm3 which reduced 
significantly to 142.3±8.6 mm3 after using GnRH agonists (goserelin), 
after 6 months of using LNG-IUS (Mirena) is reduced significantly to 
109.8±9.4 mm3 and finally after another 6 months (1 year) it continues 
to reduced significantly to 91.5±6.0 mm3, as illustrated in Fig. 3.
There was a significant increase in Hb value from baseline to the end of 
follow-up (9.8±0.4–11.0±0.4, p<0.001), as illustrated in Fig. 4.
Table 2 shows the mean period of follow-up was 17.1±5.7, during which 
Fig. 1: Percentage change in blood volume
Fig. 2: Change in dysmenorrhea visual analog pain scale score
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25 of women had successful treatment, 6 women (18.8%) have side 
effect which was mainly spotting, and 6 women had failure (5 expulsed 
and one woman ask to remove because of the spotting and fail to show 
response), the failure occurred within the first 6 months of using LNG-
IUS, three of the patient enrolled in the study failed to show response 
and end up with hysterectomy. The histopathology of the products of 
surgery confirmed the diagnosis of diffuse adenomyosis.
Table 3 shows no significant difference in the age, parity, BMI, bleeding 
volume, and pain score according to the outcome of implantation. 
Although the baseline uterine volume and uterine volume after using 
GnRH agonists was higher in the failure implantation group, this 
difference did not reach statistical significance and this, in turn, may be 
attributed to the small sample size of our study.
Both volume of uterine at baseline and percentage of change from 
baseline to the stopping of goserelin had poor ability to predict failure 
of implantation, while the final uterine volume after using goserelin 
had fair ability to predict failure of implantation with uterine volume 
>145 mm3 predicting best failure, the positive likelihood ratio for 
this cut point is 1.53 which indicate it increases the conformation by 
0–15%, while the negative likely hood ratio is 0.32 which indicate it had 
the ability to add 15–30% exclusion to the prediction of failure. This 
indicates that the final uterine volume after using goserelin is better for 
predicting success that failure as illustrated in Table 4 and Fig. 5.
DISCUSSION
GnRH agonist was previously the first drug of choice used in the 
treatment of adenomyosis. It causes reduction in uterine volume, 
menstrual blood loss, and relief of dysmenorrhea. However, due 
to its adverse side effects and the possible rebound effect after 
discontinuation of treatment, their use is limited to a short period of 
time (3–6 months) and to certain conditions [5,6].
On the other hand, evidence supports that LNG-IUS is used as an 
effective treatment reducing adenomyosis-associated menorrhagia with 
a significant increase in Hb, hematocrit, and serum ferritin [9,19]. The 
efficacy of the LNG-IUS treatment has been widely assessed in decreased 
AUB and uterine volume at 12 months and has been extremely effective 
in resolving pain associated with adenomyosis [20]. Fedele et al. [19] and 
Kelekci et al. studies also showed that the LNG-IUS results in significant 
improvements in adenomyosis-associated HMB and dysmenorrhea [21]. 
However, its efficacy in treating larger uterine adenomyosis is not clear, 
and its ability to decrease uterine volume has not yet been determined. 
In clinical practice, an enlarged uterus (uterine volume ˃12-week 
gestation) is the main causes of LNG-IUS expulsion [22].
Rapid review of literature that studies the clinical efficacy of combing 
GnRHa-LNG-IUS in the treatment of symptomatic adenomyosis were 
few.
Our study design was to gain the advantages of using GnRHa for short 
period of time to control symptoms rapidly and treat anemia and to 
reduce the uterine volume by which it can decrease the risk of expulsion 
if we use LNG-IUS initially. The carry on effect of GnRHa supported by 
the advantages of use LNG-IUS then after can probably be a good option 
for medically ill women when surgery carry more risk for them.
Our study showed that there were significant improvements in 
dysmenorrhea and pelvic pain, as well as significant decrease in the 
menstrual blood loss, especially after the end-of-using GnRHa in which 
most of the women became amenorrhea or with minimum menstrual 
blood loss and this improvement, was maintained through after 
insertion of LNG-IUS till the end of the follow-up period.
Fig. 3: Uterine volume change during the treatment periods
Fig. 4: Change in hemoglobin in the study
Fig. 5: Receiver operating characteristic curve of the predictors of 
failure of implantation
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34.9% reduction in the uterine volume after discontinuation of GnRHa 
(12.9% from uterine volume 6 m after LNG-IUS insertion).
Zhang et al. at 2013 studies the efficacy of LNG-IUS with LNG-IUS for 
the treatment of adenomyosis, and they end up in a conclusion that 
this regime was efficacious in patients with enlarged adenomyosis with 
significant improvement of pain and bleeding and low IUD expulsion 
rate which in turn allowed patients to avoid surgical treatment. In 
their study, they use uterine volume of 180 cm3 as a cutoff level to stop 
GnRHa and insert LNG-IUS and that the reduction in uterine volume 
was mainly attributed to the use of GnRHa only and the role of LNG-
IUS was to maintain the inhibitory state of the uterus after GnRHa 
treatment and in turn effectively controlled adenomyosis [22].
Lee et al. in their study showed that the optimum cutoff value of the 
uterine volume of ˃150 mL was significantly associated with LNG-
IUD failure. Their study also showed that the mean uterine volume 
decreased significantly (10%) after 6 months of insertion of LNG-
IUS [23].
Sheng et al. study also showed a significant reduction in uterine 
volume after using LNG-IUS and this reduction was mainly seen in 
the first 1 year of use. The study also showed that LNG-IUS appears 
to be an effective method in relieving dysmenorrhea associated with 
adenomyosis during 3 years making it a good long-term alternative for 
the treatment of adenomyosis [24].
In regard to the rate of expulsion of LNG-IUD, it is around 9-10% 
when it used as contraceptive purposes [25,26] increase up to 25% 
when LNG-IUD used in adenomyosis [27] and reach 37.5% when 
used in large adenomyosis (gestational age 12 weeks during the 
pelvic examination)  [28]. The expulsion rate decrease significantly 
to 9.5% when LNG- IUD insertion was preceded by the use of GnRH 
agonists [22].
In our study, the expulsion rate was 15.6% which usually occurred 
within the first 6 months of insertion of LNG- IUD.
Recommendation of our study is to use case–control study with larger 
sample size and longer follow-up period.
CONCLUSION
Sequential treatment protocol of GnRH agonist (GnRHa) - LNG-
IUS in symptomatic and relatively large adenomyosis (˃150 cm3) is 
effective in relieving symptoms significantly by improving pain and 
heavy menstrual loss as well as its effectiveness in decreasing uterine 
volume with less possible expulsion rate. This protocol can be good 
substitutions to surgery, especially in medically ill women were surgery 
carry more risk.
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Table 1: Basic clinical characteristics
Variables Value
Number 32
Age (years), mean±SD (range) 46.6±2.69 (39–52)
Parity, mean±SD (range) 3.5±0.9 (2–5)
BMI, mean±SD (range) 27.9±1.1 (26–30)
Bleeding volume, mean±SD (range) 180.0±16.2 (150–220)
Dysmenorrhea (VAS) , mean±SD (range) 4.75±0.80 (3–6)
Mild dysmenorrhea, no. (%) 2 (6.3%)
Moderate dysmenorrhea, no. (%) 30 (93.8%)
Associated chronic diseases
Hypertension, no. (%) 20 (62.5%)
DM, no. (%) 25 (78.1%)
Heart, no. (%) 6 (18.8%)
Others, no. (%) 2 (6.3%)
Past surgical history, no. (%) 25 (78.1%)
Curettage, no. (%) 16 (50%)
CS, no. (%) 15 (46.9%)
SD: Standard deviation, range (minimum–maximum)
Table 2: Final outcome at the end of the study
Variables Value
Expulsion, no. (%) 5 (15.6%)
Side effect, no. (%) 6 (18.8%)
Final outcome
Success, no. (%) 25 (78.1%)
Failure, no. (%) - [expulsion+ask to remove] 6 (18.8%)
Duration of follow-up (months), mean±SD (range) 17.1±5.7 (5–24)
Hysterectomy, no. (%) 3 (9.4%)
SD: Standard deviation, range (minimum – maximum)
Table 3: Comparison between different variables in relation to 
the outcome of implantation
Variables Outcome p
Success Failure
Number 25 7 -
Age, mean±SD 46.7±2.8 46.4±2.4 0.831
Parity, mean±SD 3.5±0.9 3.4±1.0 0.894
BMI, mean±SD 27.8±1.1 28.4±1.4 0.177




Uterine volume baseline, 
mean±SD
194.0±29.2 208.6±35.8 0.274
Uterine volume after 
goserelin, mean±SD
141.0±8.2 147.1±9.0 0.096
Baseline Hb, mean±SD 9.8±0.3 9.6±0.4 0.141
SD: Standard deviation, Hb: Hemoglobin, BMI: Body mass index
Table 4: Utility of uterine volume as predictor of failure in implantation of Marina
Variables AUC Interpretation Cut point PPV (%) NPV (%) +LH −LH
At baseline 0.666 Poor >180 33.3 92.9 1.79 0.27
After using goserelin 0.749 Fair >145 50.0 87.5 3.57 0.51
Change from baseline to stopping goserelin 0.586 Poor ≤-23.7 30.0 91.7 1.53 0.32
PPV: Positive predictive value, NPV: Negative predictive value, +LH: Positive likelihood ratio, −LH: Negative likelihood ratio
The baseline uterine volume was 197.2±30.7 mm3 which reduced 
significantly to 142.3±8.6 mm3 after using GnRHa with 26.7% reduction 
from its initial size. Further reduction encountered after 6 months 
of using Mirena where the uterine volume reduced significantly 
to 109.8±9.4 mm3 with 22% reduction from the uterine volume 
after discontinuation of GnRHa and finally it continues to reduced 
significantly to 91.5±6.0 mm3 1 year after LNG-IUS insertion with 
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